| A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer |
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks for lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617. The study also seeks to further characterize any other serious adverse reaction(s) over the long-term in adults with prostate cancer. Participants should enroll into the LTFU study after parent treatment study requirements..
Organe: Prostate
Maladie: Cancer de la prostate
